CL2021000269A1 - Métodos para tratar trastornos neurodegenerativos - Google Patents

Métodos para tratar trastornos neurodegenerativos

Info

Publication number
CL2021000269A1
CL2021000269A1 CL2021000269A CL2021000269A CL2021000269A1 CL 2021000269 A1 CL2021000269 A1 CL 2021000269A1 CL 2021000269 A CL2021000269 A CL 2021000269A CL 2021000269 A CL2021000269 A CL 2021000269A CL 2021000269 A1 CL2021000269 A1 CL 2021000269A1
Authority
CL
Chile
Prior art keywords
methods
neurodegenerative disorders
treat neurodegenerative
treat
disorders
Prior art date
Application number
CL2021000269A
Other languages
English (en)
Spanish (es)
Inventor
John Hey
Petr Kocis
Martin Tolar
Neil William Flanzraich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021000269A1 publication Critical patent/CL2021000269A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CL2021000269A 2018-08-01 2021-02-01 Métodos para tratar trastornos neurodegenerativos CL2021000269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862713061P 2018-08-01 2018-08-01

Publications (1)

Publication Number Publication Date
CL2021000269A1 true CL2021000269A1 (es) 2021-06-18

Family

ID=67614642

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000269A CL2021000269A1 (es) 2018-08-01 2021-02-01 Métodos para tratar trastornos neurodegenerativos

Country Status (27)

Country Link
US (2) US12083082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3829563B1 (cg-RX-API-DMAC7.html)
JP (1) JP7573512B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716959B1 (cg-RX-API-DMAC7.html)
CN (1) CN112867485A (cg-RX-API-DMAC7.html)
AU (1) AU2019315853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001739A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000269A1 (cg-RX-API-DMAC7.html)
DK (1) DK3829563T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190406A1 (cg-RX-API-DMAC7.html)
ES (1) ES3011716T3 (cg-RX-API-DMAC7.html)
FI (1) FI3829563T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250206T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070101T2 (cg-RX-API-DMAC7.html)
IL (1) IL280424B2 (cg-RX-API-DMAC7.html)
LT (1) LT3829563T (cg-RX-API-DMAC7.html)
MX (1) MX2021001287A (cg-RX-API-DMAC7.html)
MY (1) MY206530A (cg-RX-API-DMAC7.html)
PH (1) PH12021550213A1 (cg-RX-API-DMAC7.html)
PL (1) PL3829563T3 (cg-RX-API-DMAC7.html)
PT (1) PT3829563T (cg-RX-API-DMAC7.html)
RS (1) RS66516B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100767XA (cg-RX-API-DMAC7.html)
SI (1) SI3829563T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500080T1 (cg-RX-API-DMAC7.html)
UA (1) UA130011C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020028290A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.
PH12021553196A1 (en) * 2019-06-17 2022-11-07 Alzheon Inc Methods for treating neurodegenerative disorders
AU2022405026A1 (en) * 2021-12-09 2024-06-20 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
SI2089417T1 (sl) * 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2014121083A1 (en) * 2013-01-31 2014-08-07 President And Fellows Of Harvard College Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition
ES2960625T3 (es) * 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
EP3347002B1 (en) * 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
MX2021001287A (es) * 2018-08-01 2021-07-15 Alzheon Inc Métodos para tratar trastornos neurodegenerativos.

Also Published As

Publication number Publication date
EP3829563A1 (en) 2021-06-09
US20250213507A1 (en) 2025-07-03
ES3011716T3 (en) 2025-04-08
EA202190406A1 (ru) 2021-10-15
BR112021001739A2 (pt) 2021-04-27
HUE070101T2 (hu) 2025-05-28
AU2019315853A1 (en) 2021-03-18
KR102716959B1 (ko) 2024-10-11
SMT202500080T1 (it) 2025-03-12
US12083082B2 (en) 2024-09-10
RS66516B1 (sr) 2025-03-31
LT3829563T (lt) 2025-02-25
PL3829563T3 (pl) 2025-04-07
IL280424B2 (en) 2025-01-01
SI3829563T1 (sl) 2025-05-30
MY206530A (en) 2024-12-19
SG11202100767XA (en) 2021-02-25
AU2019315853B2 (en) 2025-05-01
JP2021533128A (ja) 2021-12-02
MX2021001287A (es) 2021-07-15
EP3829563B1 (en) 2024-11-20
UA130011C2 (uk) 2025-10-15
CN112867485A (zh) 2021-05-28
IL280424B1 (en) 2024-09-01
KR20210039415A (ko) 2021-04-09
US20210315847A1 (en) 2021-10-14
PH12021550213A1 (en) 2021-11-03
FI3829563T3 (fi) 2025-02-17
CA3108150A1 (en) 2020-02-06
WO2020028290A1 (en) 2020-02-06
PT3829563T (pt) 2025-02-18
HRP20250206T1 (hr) 2025-04-11
DK3829563T3 (en) 2025-02-24
JP7573512B2 (ja) 2024-10-25
IL280424A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX375424B (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
CR20160352A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX375372B (es) COMPOSICIONES DE COMPUESTOS DE MOLÉCULA PEQUEÑA Y USO DE LOS MISMOS COMO INHIBIDORES TrKA.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
CR20200214A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
CU20160151A7 (es) 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
ECSP17035415A (es) 2-Amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de BACE1
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX377304B (es) Derivados de piperazina como moduladores de los receptores x del hígado.
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ
MX2021001287A (es) Métodos para tratar trastornos neurodegenerativos.
MA47595A (fr) Méthodes de traitement d&#39;affections neurodégénératives
MX2016012645A (es) Composiciones y metodos para tratar enfermedades neurodegenerativas.